Fighting for patients' access to new treatments and cures. Chief Public Affairs Officer & Head of Strategic Initiatives at @PhRMA.
Washington, DC
- Tweets 2,588
- Following 3,512
- Followers 2,777
- Likes 98
Pinned Tweet
As football season begins, fans will see hospital names on stadiums across the country. What's much harder to see is how profits generated through the 340B program are being used.
Learn more: ow.ly/Z1bm50ZLuNQ
1
90
Great few days in London joining Bank of America and McDermott Will & Schulte for conversations about the future of biopharma. From China and AI to global competition for R&D and manufacturing, one thing is clear: U.S. leadership in medical innovation isn’t guaranteed.
We should meet that competition by making America the best place in the world to research, develop and manufacture the next generation of medicines.
1
322
PBMs are increasingly positioning themselves as champions of affordability. But for many patients, the experience and hard data tell a different story. Three PBMs control 80% of the prescription drug market and have significant influence over which medicines patients can access, what they'll pay and the hurdles they may face accessing their doctor-prescribed treatments.
Patients deserve results, not a new narrative. Learn more: ow.ly/XHT050ZPMha
1
79
50 cents of every dollar spent on medicines goes to middlemen. That’s why the work on #PBM reform isn’t finished.
Enjoyed talking with @BrodyMullinsDC from @the535news about what patients are still facing — and how sustained public affairs campaigns can help put overlooked issues on the policy agenda.
Watch my conversation: ow.ly/xyox50ZP9Km
3
4
213
PDUFA is critical to patients and Congress most move swiftly to reauthorize it. Without it, we put America’s biopharmaceutical leadership at risk, and American patients will pay the price.
Learn more: ow.ly/13cI50ZNZqC
1
96
PBMs are working hard to convince patients and policymakers that they’re lowering health care costs. But changing the talking points doesn’t change the facts: PBMs negotiate billions in rebates and discounts, with no guarantee that patients see those savings at the pharmacy counter. Patients deserve more transparency and accountability from the middlemen controlling access to medicines. Learn more at PhRMA.org/PBMs.
56
Pennsylvania shows what smart policy can do. Its leaders made the state attractive for biopharmaceutical investment, and the state has reaped the rewards in jobs and growth. America should take note. Read more about last week’s @axios event: ow.ly/Z94Y50ZNyNt
77
Keeping the U.S. at the forefront of developing new medicines starts with supporting the research, talent and investment happening in states like Pennsylvania.
Tune into @axios Live for a closer look at what it will take to keep that momentum going>>>
Pennsylvania is a biopharmaceutical hub, home to an ecosystem of world-class research institutions, a strong workforce pipeline and investment in advanced manufacturing.
Watch LIVE ▶️ @Axios Beyond the Breakthrough: Pennsylvania’s Innovation Edge!
nitter.net/i/broadcasts/1PKqrNzkb…
65
Since 2017, the FDA has approved a growing number of cell and gene therapies that target the root causes of serious diseases and can offer long-term, potentially curative results. Our health care system must evolve as these advances continue.
Learn more: ow.ly/YgYb50ZJxTe
2
90
One key topic from @steveubl's conversation with @BrodyMullinsDC and @camoosomiller on @decidersshow: Where biopharmaceutical research happens matters.
China is investing heavily in research and clinical trial infrastructure. As Steve points out, the U.S. needs policies that make it easier to develop the next generation of medicines here.
1
141
Expanding biopharmaceutical manufacturing in the U.S. also requires investing in the workforce behind it.
Upskilling, reskilling and talent development will be critical to creating high-quality jobs and supporting long-term manufacturing growth.
ow.ly/hekW50ZGG0w
91
The FDA's approval of the first at-home starting dose for an Alzheimer's treatment is an important milestone. Progress isn't only about developing new medicines. It's also about improving how patients receive them and making treatment more manageable for patients and caregivers.
ow.ly/73Aj50ZFKA5
1
79
The numbers speak for themselves. America is where the world looks for the next breakthrough. Policymakers should be focused on building on that success and encouraging even more investment in the search for new treatments and cures.
PhRMA member companies have invested more than $900 billion in the search for new treatments and cures, with more than $110 billion invested in 2025 alone.
Protecting the policies that make innovation possible helps keep America the global leader in biopharmaceutical R&D.
ow.ly/1qN150ZzZro
101
No American should have to fight to access medicines prescribed by their doctor. That’s why we launched America's Medicines, making it easier for patients, caregivers and providers find more affordable ways to purchase prescribed medicines, all in one place.
54
PBM reform didn't happen overnight.
As @steveubl discusses, years of educating policymakers about PBMs and their incentives helped lay the groundwork for reforms from Congress, the FTC and the Department of Labor that can help the market work better for patients.
Watch Steve's conversation with @BrodyMullinsDC and @camoosomiller on @decidersshow.
2
190
A golf ball can have as many as 68 patents covering different features. While medicines have an average of… just five. Critics often dismiss new uses or improvements of medicines as meaningless gaming of the IP system.
But here’s the bottom line: Biopharma innovation builds on itself. Each new discovery adds to previous advances, helping more patients live healthier lives.
ow.ly/EVEs50ZyEPN
1
122
The 340B program has changed dramatically over the past decade. Today, nearly two-thirds of U.S. pharmacies participate in 340B, yet there's little transparency into how patients benefit. Greater transparency and accountability are needed.
ow.ly/jBT450ZwHFe
1
100
For decades, America has led the world in developing new medicines. That lead is not guaranteed.
China has a long-term plan to dominate life sciences, and the policy choices we make in Washington over the next few years will decide who leads next. Here's how we stay ahead:
- Make America the most attractive place in the world to invest, do research, and bring medicines to patients
- Ensure patients can actually access and afford the medicines their doctors prescribe
- Do no harm to the system that built our lead — no price controls, no undermining IP
Watch the full conversation below. ⬇️
In an exclusive interview with The Hill, Robert Zirkelbach, Chief Public Affairs Officer at @PhRMA, on how the U.S. can continue its worldwide dominance in medical science:
"We need a national strategy to ensure that America is the most attractive place in the world to invest, do research, and bring medicines to patients." 🧪🧑🔬
#HillNationSummit
94
